Biologic Therapies and New Treatments for Lupus

By: Dr. Robert Katz, Rheumatologist

Recent studies are demonstrating promising results for nipocalimab, a monoclonal antibody that has shown effectiveness compared with placebo. Nipocalimab works by reducing circulating immunoglobulin G (IgG) levels, including certain autoimmune antibodies. It is important to note that, as of now, nipocalimab has not yet been approved by the FDA for lupus.

One of the newer treatments approved for lupus, particularly lupus nephritis (kidney disease), is Gazyva (obinutuzumab). Obinutuzumab is a monoclonal antibody that targets B cells and has shown encouraging results in people with lupus nephritis.

There are also several promising medications in the lupus development pipeline, including litifilimab and nipocalimab.

Currently approved biologic therapies for lupus include Benlysta (belimumab) and Saphnelo (anifrolumab). These medications have provided additional treatment options for people whose lupus is not adequately controlled with traditional therapies.

The “-mab” ending in medications such as belimumab, anifrolumab, obinutuzumab, and nipocalimab indicates that the medication is a monoclonal antibody, designed to target a specific molecule or pathway involved in the immune system.

Overall, the development of biologic therapies represents an exciting advancement in lupus treatment. Researchers are continuing to study medications that target different parts of the immune system, giving people with lupus and their healthcare providers more treatment options.